This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Eli Lilly's Lesson in Long-Term Thinking

It's easy to let short-term necessities overshadow long-term goals. Who cares about five-year plans when you've got to sort through this week's inventory and meet this month's payroll?

But muddling along from day to day only takes you so far. Sometimes you've got to look at the future of your business to figure out the right moves to make today.

Take Eli Lilly (LLY - Get Report). This week, the company announced it would pay $6.5 billion to buy ImClone (IMCL), the biotech company once infamous for its connection to the Martha Stewart insider-trading scandal.

This might not seem like the best time for a big corporate buyout. With the economy almost certainly about to plunge into a recession and consumers jittery, Lilly would only go after a deal this big if it had a lot riding on it. ImClone's new-drug pipeline may just be the key to Lilly's future.

Have you put similar thought into your long-term prospects? Considered how your products will sell in three years? Ten years? If not, you may be missing out on opportunities right now.

Pharmaceutical companies have no choice but to look long-term, given how much time goes into developing and testing drugs. That means execs must not only assess how they're doing today, but also place bets on where they'll be in the future. It's hard to know what will pay off, as promising drugs may look great in the lab but turn out to be duds in clinical trials. That's why execs have to keep plenty of options in the development pipeline, rather than allow profits to depend on one or two blockbuster products.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
IMCL $0.14 0.00%
LLY $76.46 0.00%
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs